| You are here: Home: BCU 8|2003: Eric P Winer, MD: Select publications
Select publications
Publications discussed by Dr Winer
Burstein HJ et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19(10):2722-30. Abstract
Burstein HJ et al. Multicenter Phase II study of trastuzumab (herceptin; H) and vinorelbine (navelbine; N) as first-line therapy for HER2 overexpressing metastatic breast cancer (HER2+ MBC). Proc ASCO 2002;Abstract 211.
Burstein HJ et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing Stage II or III breast cancer: A pilot study. J Clin Oncol 2003;21(1):46-53. Abstract
Burstein HJ et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter Phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21(15):2889-95. Abstract
Howell A et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20(16):3396-403. Abstract
Mauriac L et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: Combined results from two multicentre trials. Eur J Cancer 2003;39(9):1228-33. Abstract
Osborne CK et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract
Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract
Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract
Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract
Endocrine therapy in the metastatic setting
Bundred N, Howell A. Fulvestrant (Faslodex): Current status in the therapy of breast cancer. Expert Rev Anticancer Ther 2002;2(2):151-60. Abstract
Carlson RW. Sequencing of endocrine therapies in breast cancer—Integration of recent data. Breast Cancer Res Treat 2002;75(Suppl 1):S27-32; discussion S33-5. Abstract
Costantino J. The impact of hormonal treatments on quality of life of patients with metastatic breast cancer. Clin Ther 2002;24(Suppl C):C26-42. Abstract
Dirix LY et al. Open-label, multicenter, controlled study of exemestane (E-Aromasin®) with or without celecoxib (Cx - Celebrex®) in postmenopausal women with advanced breast cancer (ABC) progressed on tamoxifen (T). Breast Cancer Res Treat 2002;Abstract 269.
Howell A. Postmenopausal women with advanced breast cancer who progress on fulvestrant or tamoxifen retain sensitivity to further endocrine therapies. Breast Cancer Res Treat 2002;Abstract251.
Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast cancer: Survival analysis from a Phase III trial. Proc ASCO 2003;Abstract 178.
Monnier A et al. Time to progression and tumor response according to estrogen receptor status in the international Phase III study of letrozole (Femara®) and tamoxifen as first-line hormonal therapy for advanced breast cancer. Breast Cancer Res Treat 2002;Abstract 257.
Morris C, Wakeling A. Fulvestrant (‘Faslodex')—A new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer 2002;9(4):267-76. Abstract
Mouridsen H et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21(11):2101-9. Abstract
Parker LM. Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer. Clin Ther 2002;24(Suppl C):C43-57. Abstract
Parker L, Webster A. Greater duration of response in patients receiving fulvestrant (‘Faslodex') compared with those receiving anastrozole (‘Arimidex'). Proc ASCO 2002;Abstract 160.
Perey L et al. Fulvestrant (‘faslodex') as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors. Breast Cancer Res Treat 2002;Abstract 249.
Piccart M et al. Oestrogen receptor downregulation: An opportunity for extending the window of endocrine therapy in advanced breast cancer. Ann Oncol 2003;14(7):1017-25. Abstract
Rose C. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. Am J Clin Oncol 2003;26(4 Suppl):S9-S16. Abstract
Steger GG et al. Fulvestrant beyond the second hormonal treatment line in metastatic breast cancer. Proc ASCO 2003;Abstract 78.
Thuerlimann B et al. Anastrozole (‘arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind crossover SAKK Trial 21/95 – a sub-study of Anastrozole Trial 0027. Breast Cancer Res Treat 2002; Abstract 255.
Vergote I et al. Postmenopausal women who progress on fulvestrant (‘Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79(2):207-11. Abstract
|
